Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
~60% reduction from baseline in a post-hoc analysis CORALreef HeFH (303 patients): 59% placebo-adjusted LDL-C reduction at week 24 Meaningful reductions also seen in non-HDL-C (5254%) and ApoB (4850%) Safety profile broadly similar to placebo
The results demonstrated a significant increase in the abundance of SCFA-producing microbes, which are associated with improved gut health
Regulatory note: The FDA added injectable GHK-Cu to a high-risk compounded substance list in September 2023
How many treatments are typically needed to see results
Investigators have proposed that GHK-Cu's central function is to deliver copper to fibroblasts in a controlled, non-toxic form buffering against the redox damage that free Cu would otherwise cause [4]
US$ 23.55
US$ 21.87
US$ 29.31
US$ 23.29
US$ 28.90
